Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Semler Scientific, Inc. filings document its common-stock status, material events and public-company reporting history. Recent regulatory records include Form 25 disclosure for removal of the common stock from Nasdaq listing and registration, and Form 15 certification covering termination or suspension of Exchange Act reporting obligations for the class of securities.
The company's 8-K filings cover material agreements, shareholder voting matters, governance items, capital-structure disclosures and operating and financial results. Filing categories also address risk factors and clinical or regulatory matters tied to Semler Scientific's healthcare technology activities, alongside disclosures related to its Bitcoin treasury strategy.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The message notes that Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction and that an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval.
The communication includes extensive forward-looking statement cautions and directs investors to the SEC’s website for free copies of the S-4 and related documents. It also states that directors, officers and employees of both companies may be participants in the proxy solicitation and concludes with a standard “no offer or solicitation” disclaimer.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific. Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement, proxy statement and prospectus.
A definitive proxy will be sent to Semler Scientific stockholders to seek approval. The notice includes forward-looking statement cautions and clarifies it is not an offer or solicitation. Investors can access related SEC filings for full details.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction, and a combined information statement/proxy statement/prospectus will be delivered to Semler Scientific stockholders to seek their approval.
The notice includes standard forward‑looking statement cautions and directs investors to the SEC’s website and company investor relations pages for the Registration Statement, proxy materials, and related filings. It also identifies that directors, officers, and employees of both companies may be participants in the proxy solicitation. The communication states it is not an offer to sell or solicit the purchase of securities.
Strive, Inc. reposted a communication related to its proposed business combination with Semler Scientific, Inc. The notice includes a comprehensive cautionary statement about forward‑looking statements and highlights risks and uncertainties that could cause actual results to differ.
Strive has filed a Form S-4 Registration Statement to register Class A common stock to be issued in connection with the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. Investors are directed to the SEC’s website and company investor sites for free access to these materials.
The communication also states it is not an offer or solicitation to buy or sell securities, and that any offer will only be made by a prospectus meeting Securities Act requirements or pursuant to an applicable exemption.
Strive, Inc. shared a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive has filed a Form S-4 registration statement to register Class A common stock to be issued in the transaction, which will include an Information Statement/Proxy Statement/Prospectus. Semler stockholders will receive these materials to consider and vote on the proposed deal.
The communication includes standard forward‑looking statements and risk cautions, notes that certain directors and officers may be participants in the proxy solicitation, and provides links to obtain SEC filings at no cost. It also states this is not an offer or solicitation to buy or sell securities; any offer will be made only by a prospectus meeting Securities Act requirements.
Strive, Inc. announced a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction. A combined information statement, proxy statement, and prospectus will be sent to Semler Scientific stockholders to seek approval. The communication includes cautionary forward-looking statements, identifies potential proxy participants, and states that no offer or solicitation is being made. Investors are directed to the SEC’s website and company investor pages for the S-4 and related materials.
Strive, Inc. shared a communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The companies note that a Form S-4 registration statement has been filed to register Strive Class A common stock to be issued in the transaction and will include an information statement, proxy statement, and prospectus.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes customary forward‑looking statements and urges investors to read SEC filings when available for important details.
Strive, Inc. filed investor communications for its proposed business combination with Semler Scientific (SMLR), sharing details from a recent podcast on its capital structure and preferred equity strategy. Strive highlighted the IPO of its perpetual preferred, SATA, which was upsized from $125 million to $200 million and initially offered at $80 per share with a 12% stated dividend on a $100 stated amount.
The company discussed managing SATA to trade near $100, with a target range of $95–$105, a dividend rate floor at 1‑month SOFR, cumulative dividends with step-up penalties up to 20% if suspended, a call feature at $110, and a policy not to reduce the dividend when trading below $99. Strive also noted a 12‑month dividend reserve held in cash.
Proceeds were used to expand Bitcoin holdings to 7,525 BTC. Illustrative coverage metrics cited include Bitcoin holdings of roughly 3.8x the SATA notional and about 32.7x annual dividend coverage, based on an example with $200 million preferred outstanding and $24 million annual dividends. The discussion reiterated the planned combination with Semler, which was described as holding more than 5,000 BTC, and emphasized perpetual preferred equity as a core financing tool.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific, Inc. (SMLR), reposted on X.com by a Strive board member. The notice emphasizes forward‑looking statement cautions and references risks that could cause actual results to differ materially.
Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction, which will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication directs investors to the SEC’s website and each company’s investor relations pages for the Registration Statement and related materials, notes potential participants in the solicitation, and states that this is not an offer or solicitation to sell or buy securities.
Semler Scientific (SMLR) issued a Rule 425 communication regarding the proposed acquisition of Semler Scientific by Strive, Inc. Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction, and an Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval.
Investors are urged to read the Registration Statement and related materials when available. Documents will be accessible at the SEC’s website and through Strive’s and Semler Scientific’s investor relations pages. The communication notes that Strive, Semler Scientific, and certain of their directors and officers may be participants in the proxy solicitation, includes customary “no offer or solicitation” language, and provides a cautionary statement regarding forward‑looking statements and referenced risk factors.